8-K: Turning Point Brands Reports Strong Q2 2025 Growth

Turning Point Brands announced better-than-expected second quarter 2025 financial results, driven by significant growth in Modern Oral sales and increased full-year guidance.

Summary

• Net Sales for Q2 2025 increased 25.1% year-over-year to $116.6 million.
• Modern Oral Net Sales for Q2 2025 increased 651% year-over-year to $30.1 million, now accounting for 26% of total Net Sales.
• Q2 2025 Adjusted EBITDA was $30.5 million, up 14.8% over the prior year.
• Full-year 2025 Adjusted EBITDA guidance was increased to $110.0 $114.0 million from $108.0 $113.0 million.
• Full-year consolidated Modern Oral sales guidance was increased to $100.0 $110.0 million from $80.0 $95.0 million.
• Stokers segment Net Sales increased 62.9% to $69.6 million.
• Zig-Zag segment Net Sales decreased 6.9% to $47.0 million.
• Gross Profit increased 32.2% to $66.6 million.
• Net Income increased 11.3% to $14.5 million.
• Adjusted Net Income increased 4.5% to $18.0 million.
• Diluted EPS was $0.79 and Adjusted Diluted EPS was $0.98.
• Total gross debt as of June 30, 2025, was $300.0 million, with net debt at $190.1 million.
• Total liquidity as of June 30, 2025, was $176.4 million, comprising $109.9 million in cash and $66.5 million of availability under its asset-backed revolving credit facility.

Sentiment

Score: 8

Explanation: The company reported strong financial results for Q2 2025, exceeding expectations and significantly increasing guidance for its high-growth Modern Oral segment and overall Adjusted EBITDA, indicating robust operational performance and positive future prospects despite declines in a legacy segment.

Positives

• Total consolidated Net Sales increased 25.1% year-over-year to $116.6 million.
• Modern Oral Net Sales surged 651% year-over-year to $30.1 million, now comprising 26% of total Net Sales.
• Adjusted EBITDA for Q2 2025 rose 14.8% to $30.5 million.
• Increased full-year 2025 Adjusted EBITDA guidance to $110.0 $114.0 million.
• Increased full-year 2025 Modern Oral sales guidance to $100.0 $110.0 million.
• Stokers segment Net Sales increased 62.9% to $69.6 million, driven by strong Modern Oral sales and mid-single-digit MST growth.
• Gross Profit increased 32.2% to $66.6 million.
• Net Income increased 11.3% to $14.5 million.
• Diluted EPS increased to $0.79 from $0.68 year-over-year.
• Adjusted Diluted EPS increased to $0.98 from $0.89 year-over-year.
• Strong liquidity position with $176.4 million total liquidity, including $109.9 million cash.

Negatives

• Zig-Zag segment Net Sales decreased 6.9% to $47.0 million year-over-year.
• Zig-Zag segment gross profit decreased 14.0% to $23.1 million.
• Zig-Zag segment gross margin decreased 410 basis points to 49.1% due to product mix.
• Selling, general and administrative (SG&A) expenses increased to $40.3 million from $29.2 million, primarily due to white pouch-related SG&A, increased outbound freight, and sales and marketing investments.
• Increased FDA PMTA-related expenses for Modern Oral products ($1.7 million compared to $1.0 million in the prior year).
• Increased transaction-related costs ($0.6 million compared to $0.1 million in the prior year).
• Non-recurring freight costs of $0.8 million were incurred.
• Non-recurring legal costs of $0.5 million were incurred in connection with litigation related to an insurance claim.

Risks

• Factors that could cause differences in actual events from forward-looking statements include, but are not limited to, those included in the company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the SEC.

Future Outlook

The company is increasing its full-year 2025 projected Modern Oral sales guidance to $100.0 $110.0 million, up from $80.0 $95.0 million. Additionally, full-year 2025 Adjusted EBITDA guidance is raised to $110.0 $114.0 million, from $108.0 $113.0 million.

Management Comments

• Our consolidated second quarter results were better than expected.
• Modern Oral sales were $30.1 million, increasing by 35% versus prior quarter and up 651% against the prior year.
• Stokers MST and looseleaf showed modest gains with Zig-Zag flat sequentially.

Industry Context

The strong growth in Modern Oral products (e.g., white pouches like FRE and Alp Pouch) indicates a significant shift in consumer preferences towards alternative nicotine delivery methods, moving away from traditional smoking products. This trend aligns with broader public health initiatives and evolving consumer demand for less harmful or more discreet options. The decline in Zig-Zag sales (traditional smoking accessories) further underscores this industry transition, highlighting the importance of diversification into growth segments like modern oral.

Legal Proceedings

• Non-recurring legal costs of $0.5 million were incurred in connection with litigation related to an insurance claim.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and significant growth in the Modern Oral segment, potentially leading to increased share value.
• Customers: Continued availability of a diverse product portfolio, including rapidly growing Modern Oral products and established Zig-Zag and Stokers brands.
• Employees: Continued operational growth, particularly in the Modern Oral segment, may lead to job stability or expansion.
• Creditors: Improved financial health and liquidity position enhance the company's ability to meet its debt obligations.

Next Steps

• A conference call with the investment community to review financial results was scheduled for 9:30 a.m. Eastern on Wednesday, August 6, 2025.
• A replay of the webcast will be available on the company website two hours following the call.
• The company expects to submit additional FDA PMTA applications for its remaining two product lines.
• Full second quarter 2025 results will be disclosed in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Key Dates

Recommendation

The company delivered better-than-expected Q2 2025 results, highlighted by exceptional 651% year-over-year growth in its Modern Oral segment, which now constitutes a significant portion of total sales. Management's decision to raise full-year guidance for both Modern Oral sales and Adjusted EBITDA signals strong confidence in continued momentum and profitability. While the Zig-Zag segment saw a decline, the robust performance and strategic shift towards higher-growth, modern product categories position the company favorably for future expansion and market leadership in evolving consumer product landscapes. The strong liquidity and improved profitability metrics make this an attractive investment opportunity.

Keywords

Turning Point Brands, TPB, Q2 2025 Earnings, Modern Oral, Stokers, Zig-Zag, Smoking Accessories, Consumables, Financial Results, Adjusted EBITDA, Net Sales, EPS, Tobacco Alternatives, Oral Nicotine